COST-EFFECTIVENESS OF ALIROCUMAB FOR PATIENTS WITH HYPERCHOLESTEROLEMIA AT HIGH CV RISK

被引：0
|
作者：
Yang, M. C. [1 ]
Tan, E. C. H. [2 ]
机构：
[1] Natl Taiwan Univ, Taipei, Taiwan
[2] Minist Hlth & Welf, Natl Res Chinese Med, Taipei, Taiwan
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.485
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV49
引用
收藏
页码：S128 / S128
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of alirocumab in high cardiovascular-risk patients in Italy
    Povero, Massimiliano
    Pradelli, Lorenzo
    Serra, Andrea
    Fanelli, Francesca
    Gazzi, Luca
    [J]. FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2021, 22 (01)
  • [2] COST-EFFECTIVENESS ANALYSIS OF ALIROCUMAB IN HIGH CARDIOVASCULAR-RISK PATIENTS IN ITALY
    Povero, M.
    Pradelli, L.
    Fanelli, F.
    Gazzi, L.
    Serra, A.
    [J]. VALUE IN HEALTH, 2020, 23 : S490 - S490
  • [3] COST-EFFECTIVENESS OF ALIROCUMAB FOR MYOCARDIAL INFARCTION IN CHINA
    Liang, Zhe
    Chen, Qi
    Zhao, Quanming
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1565 - 1565
  • [4] COST-EFFECTIVENESS OF ALIROCUMAB FOR MYOCARDIAL INFARCTION IN CHINA
    Liang, Z.
    Chen, Q.
    Zhao, Q.
    [J]. ATHEROSCLEROSIS, 2021, 331 : E252 - E252
  • [5] COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA IN BELGIUM
    Descamps, O. S.
    Van Hout, B.
    Lindgren, P.
    Villa, G.
    Urbich, M.
    Fonarow, G. C.
    [J]. ATHEROSCLEROSIS, 2020, 315 : E36 - E36
  • [6] Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes The ODYSSEY OUTCOMES Trial
    Bhatt, Deepak L.
    Briggs, Andrew H.
    Reed, Shelby D.
    Annemans, Lieven
    Szarek, Michael
    Bittner, Vera A.
    Diaz, Rafael
    Goodman, Shaun G.
    Harrington, Robert A.
    Higuchi, Keiko
    Joulain, Florence
    Jukema, J. Wouter
    Li, Qian H.
    Mahaffey, Kenneth W.
    Sanchez, Robert J.
    Roe, Matthew T.
    Lopes, Renato D.
    White, Harvey D.
    Zeiher, Andreas M.
    Schwartz, Gregory G.
    Steg, Ph. Gabriel
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (18) : 2297 - 2308
  • [7] The cost-effectiveness of preoperative optimisation of high risk surgical patients
    AN Chamberlain
    N Harper
    S Morris
    [J]. Critical Care, 6 (Suppl 1):
  • [8] COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN SPAIN
    Villa, G.
    Lothgren, M.
    Kutikova, L.
    Lindgren, P.
    Gandra, S. R.
    Fonarow, G. C.
    Sorio, F.
    Masana, L.
    Bayes-Genis, A.
    van Hout, B.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A651 - A652
  • [9] THE COST-EFFECTIVENESS OF TAVI IN INOPERABLE AND HIGH RISK PATIENTS IN FRANCE
    Goodall, G.
    Zemanova, B.
    Candolfi, P.
    Sohlberg, A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A589 - A589
  • [10] Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain
    Villa, Guillermo
    Lothgren, Mickael
    Kutikova, Lucie
    Lindgren, Peter
    Gandra, Shravanthi R.
    Fonarow, Gregg C.
    Sorio, Francesc
    Masana, Lluis
    Bayes-Genis, Antoni
    van Hout, Ben
    [J]. CLINICAL THERAPEUTICS, 2017, 39 (04) : 771 - 786
12345